Watch RPRX. Know when insiders buy.
One email the day a filing lands. Free.
RPRX
Royalty Pharma plc
62.15
−0.10 −0.16%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
35
FLAG · insiders 25, shorts 44
Insiders, 90 days
−$6.3M
net selling · 0 buys, 4 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
3 / 15
tracked funds hold it
Calls on record
0
nobody we score has called it yet
MKT CAP $24.1BP/E 33.1DIV YIELD 1.46%FCF YIELD —REV TTM $2.5B +10.0%NET INCOME $815M −20.4%NET DEBT $8.1B52W 36.41 – 63.96SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $674.1M | +16.5% | — | $133.1M | $17.9M | −44.4% | 0.04 | $728.5M | — | — | Aug 5 |
| Q1 2026 · Mar 31 | $630.6M | +11.0% | — | $563M | $294.7M | +23.1% | 0.67 | $718.2M | — | — | Aug 5 |
| Q4 2025 · Dec 31 | $622M | +4.8% | — | $388.4M | $214.2M | +2.9% | 0.50 | $827.1M | — | — | Feb 11 |
| Q3 2025 · Sep 30 | $609.3M | +7.9% | — | $427.2M | $288.2M | −47.0% | 0.67 | $702.6M | — | — | Feb 11 |
| Q2 2025 · Jun 30 | $578.7M | +7.7% | — | $209.8M | $32.2M | −68.5% | 0.07 | $364M | — | — | Aug 5 |
| Q1 2025 · Mar 31 | $568.2M | +0.0% | — | $534.2M | $239.3M | +4909.4% | 0.55 | $596.1M | — | — | May 6 |
| Q4 2024 · Dec 31 | $593.6M | −0.4% | — | $361.5M | $208.2M | −57.9% | 0.47 | $742.5M | — | — | Feb 11 |
| Q3 2024 · Sep 30 | $564.7M | +5.3% | — | $735.1M | $544M | +654.3% | 1.21 | $703.6M | — | — | Nov 5 |
| Q2 2024 · Jun 30 | $537.3M | — | — | $269.6M | $102M | — | 0.23 | $658.2M | — | — | Aug 6 |
| Q1 2024 · Mar 31 | $568M | — | — | −$73.8M | $4.8M | — | 0.01 | $664.6M | — | — | May 8 |
| Q4 2023 · Dec 31 | $596.1M | — | — | $612.9M | $494.3M | — | 1.10 | $772.6M | — | — | Feb 11 |
| Q3 2023 · Sep 30 | $536.3M | — | — | $151.4M | $72.1M | — | 0.16 | $573.5M | — | — | Nov 6 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $2.4B | — | $1.6B | $770.9M | 32.4% | 1.78 | $2.5B | — | — | $1.2B | — |
| FY2024 · to Dec 31 | $2.3B | — | $1.3B | $859M | 37.9% | 1.91 | $2.8B | — | — | $229.7M | — |
| FY2023 · to Dec 31 | $2.4B | — | $1.5B | $1.1B | 48.2% | 2.53 | $3B | — | — | $304.8M | — |
| FY2022 · to Dec 31 | $2.2B | — | $307.1M | $42.8M | 1.9% | 0.10 | $2.1B | — | — | $0 | — |
| FY2021 · to Dec 31 | $2.3B | — | $1.4B | $619.7M | 27.1% | 1.49 | $2B | — | — | $0 | — |
| FY2020 · to Dec 31 | $2.1B | — | $1.6B | $975M | 45.9% | 1.32 | $2B | — | — | $0 | — |
Every number comes from Royalty Pharma plc's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.